Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Minda Corporation's Record Q2 Revenue Surge! Analyst DEVEN CHOKSEY Reveals New Rs 649 Target – BUY to ACCUMULATE?

Brokerage Reports

|

Updated on 10 Nov 2025, 07:22 am

Whalesbook Logo

Reviewed By

Abhay Singh | Whalesbook News Team

Short Description:

Minda Corporation reported a record-breaking Q2 FY26 with consolidated revenue of INR 15,354 million, up 19.0% year-over-year. The company also saw improvements in EBITDA margin. For the first half of FY26, revenue grew 17.7% YoY. Following this strong performance, analyst Deven Choksey has revised his rating to "ACCUMULATE" from "BUY", setting a new target price of INR 649 based on September 2027 estimates.
Minda Corporation's Record Q2 Revenue Surge! Analyst DEVEN CHOKSEY Reveals New Rs 649 Target – BUY to ACCUMULATE?

▶

Stocks Mentioned:

Minda Corporation Limited

Detailed Coverage:

Minda Corporation has announced robust financial results for the second quarter of Fiscal Year 2026 (Q2 FY26). The company achieved its highest-ever quarterly consolidated revenue at INR 15,354 million, marking a significant 19.0% year-over-year (YoY) increase and exceeding estimates by 8.2%. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at INR 1,779 million, with the margin improving by 22 basis points (bps) YoY to 11.6%. Profit After Tax (PAT) was reported at INR 846 million, with a margin of 5.5%.

For the first half of FY26 (H1 FY26), Minda Corporation's consolidated revenue reached INR 29,210 million, a 17.7% YoY growth. The EBITDA for H1 FY26 was INR 3,340 million, with an 11.4% margin, up 23 bps YoY. The PAT for the period was INR 1,500 million, maintaining a stable 5.1% margin.

Impact Analyst Deven Choksey's research report has rolled forward valuation to September 2027 estimates, valuing Minda Corporation at 33.0x Sep'27 Earnings Per Share (EPS), resulting in a target price of INR 649. The rating has been revised from "BUY" to "ACCUMULATE". This news is positive due to strong financial performance, but the rating downgrade suggests potential moderation in growth expectations or that the stock may be fairly valued at current levels, prompting a more cautious investment stance. Rating: 7/10.

Definitions: FY26: Financial Year 2025-2026. YoY: Year-over-Year, comparing performance to the same period in the previous year. EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization - a measure of a company's operating performance. PAT: Profit After Tax - the company's net profit after all expenses and taxes. EPS: Earnings Per Share - the portion of a company's profit allocated to each outstanding share of common stock. Premiumisation: Offering higher-value, more advanced products or services. Consolidated Revenue: The total revenue of a company including all its subsidiaries. Basis points (bps): A common unit of measure for interest rates and financial percentages, where 100 bps equals 1%.


Healthcare/Biotech Sector

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Novo Nordisk Lands in India with Wegovy! Emcure Partnership Sparks Pharma Race for Weight-Loss Drugs!

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Alembic Pharma Q2 BEATS Expectations! 🚀 ICICI Securities REVS UP Target - Should You BUY?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

Divi's Lab Stock Alert! 🚨 Analyst Downgrade: Peptide Growth & Entresto Woes EXPLAINED - Profit Booking Advised?

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

BIG Pharma Win! Alembic Pharmaceuticals Secures US FDA Approval for Migraine Injection!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!

ICICI Securities Goes Bullish on Aurobindo Pharma: Target Price Hiked to ₹1,350!


Transportation Sector

Shipping Corp Shares CRASH 8.5% After Disappointing Q2 Earnings! Profits Halved - Is This Your Sign to Sell?

Shipping Corp Shares CRASH 8.5% After Disappointing Q2 Earnings! Profits Halved - Is This Your Sign to Sell?

Shipping Corp Shares CRASH 8.5% After Disappointing Q2 Earnings! Profits Halved - Is This Your Sign to Sell?

Shipping Corp Shares CRASH 8.5% After Disappointing Q2 Earnings! Profits Halved - Is This Your Sign to Sell?